If You Invested in Biofrontera Inc (BFRI)

Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company focused on the development and commercialization of pharmaceutical products for dermatology, with a particular emphasis on photodynamic therapy (PDT). According to company disclosures, Biofrontera commercializes a portfolio of products used for the treatment of dermatological conditions, especially actinic keratoses (AKs), which are pre-cancerous skin lesions, and is advancing its PDT platform for additional skin disease indications.

The company’s primary product franchise centers on Ameluz® in combination with its RhodoLED® and BF‑RhodoLED® XL red light lamps (together, the RhodoLED lamp series). These products are used in photodynamic therapy for the treatment of actinic keratoses and are being studied and positioned for broader use in dermatology. Biofrontera describes itself as specializing in PDT in dermatology and in the commercialization of dermatological products in the United States.

Core business and photodynamic therapy focus

Biofrontera’s business is built around PDT-based treatments for skin disorders. The company states that its products are used for the treatment of actinic keratoses and are in development for additional indications. In multiple company communications, Biofrontera highlights its strategy to expand the clinical utility of its PDT platform and to advance new growth opportunities by pursuing label expansions for Ameluz®-PDT.

Actinic keratosis is described by the company as the most common pre-cancerous skin lesion caused by chronic sun exposure, with the potential to progress to squamous cell carcinoma if left untreated. AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or backs of the hands. Biofrontera’s PDT approach with Ameluz® and RhodoLED® targets these lesions and is already approved for certain body areas, with further indications under clinical and regulatory review.

Key products and indications

Based on the company’s own descriptions and press releases, Biofrontera’s core commercial and development activities include:

• Ameluz® (aminolevulinic acid hydrochloride) gel, 10% used in combination with red light PDT for the treatment of mild to moderate actinic keratoses on the face and scalp, with clinical programs aimed at expanding use to additional body areas.
• RhodoLED® and BF‑RhodoLED® XL red light lamps, which provide the light source required for Ameluz®-PDT treatments. These lamps are an integral part of the company’s PDT platform and are used in clinical studies as well as routine practice.

The company reports that its licensed and now acquired products, including Ameluz® and the RhodoLED lamp series, are used for the treatment of actinic keratoses and that it is pursuing additional indications. These include:

• Actinic keratosis on non-face and scalp areas: Biofrontera has conducted a Phase 3 clinical trial evaluating Ameluz®-PDT for AKs on the extremities, neck and trunk, and a Phase 1 pharmacokinetics study under maximal-use conditions on peripheral body areas. The company has indicated that these data are intended to support a supplemental New Drug Application (sNDA) to expand the label to all peripheral body areas.
• Superficial basal cell carcinoma (sBCC): Biofrontera has submitted an sNDA to the U.S. Food and Drug Administration (FDA) seeking approval of Ameluz®-PDT for the treatment of superficial basal cell carcinoma. The submission includes Phase 3 efficacy and safety data, one-year follow-up outcomes, and integrated analyses from U.S. and European studies.
• Acne vulgaris: The company is conducting a Phase 2 clinical study evaluating Ameluz®-PDT for moderate to severe acne vulgaris. Biofrontera notes that acne vulgaris is one of the most commonly diagnosed skin disorders in the United States and that it sees an unmet need for in-office, non-systemic treatment options.

Strategic focus and asset ownership

Biofrontera has undertaken a series of corporate and transactional steps to consolidate and strengthen its PDT franchise in the United States. In a strategic transaction with its former parent company, Biofrontera AG, Biofrontera Inc. entered into an Asset Purchase Agreement and an Earnout Agreement to acquire all U.S. rights to Ameluz® and RhodoLED®. The company reports that it has acquired:

• All U.S. assets and rights related to Ameluz® and RhodoLED®, including the New Drug Application (NDA) and Investigational New Drug Application (IND).
• Manufacturing rights and contracts, intellectual property, and associated personnel in the United States.

Following the transfer of the Ameluz® and RhodoLED® NDA and IND, Biofrontera states that it now assumes full responsibility for manufacturing, regulatory affairs, quality management, pharmacovigilance, and commercialization of Ameluz® and the RhodoLED® portfolio in the U.S. The company has also reported the transfer and assignment of multiple U.S. patents, U.S. patent applications, international patent filings or registered designs for the RhodoLED lamps, and associated trademarks, thereby consolidating its intellectual property position around its PDT platform.

In connection with this strategic transaction, Biofrontera replaced a prior transfer-pricing model with a royalty-based earnout structure, under which it pays a percentage of U.S. net sales of Ameluz® as an earnout to Biofrontera AG. The company has described this change as reducing its cost of goods and improving its gross margin profile, with the goal of supporting a path toward profitability as Ameluz® sales grow.

Portfolio optimization and divestiture activity

Alongside its focus on photodynamic therapy, Biofrontera has taken steps to streamline its product portfolio. The company announced that it has divested its U.S. license for Xepi® (ozenoxacin) Cream, 1%, an antibiotic cream approved by the FDA for the treatment of impetigo due to certain bacteria, to Pelthos Therapeutics Inc. Under the asset purchase agreement, Biofrontera is eligible for upfront consideration and potential milestone payments tied to future net sales of Xepi®.

Biofrontera has stated that the proceeds from this transaction are intended to bolster its cash position and support the growth of its commercial PDT platform, including efforts to expand Ameluz® into additional indications such as broader AK coverage, superficial basal cell carcinoma, and acne vulgaris.

Regulatory and clinical development activities

Regulatory and clinical development are central to Biofrontera’s business model. The company highlights several ongoing and recent activities:

• Phase 3 AK study (extremities, neck, trunk): A Phase 3 clinical trial evaluating Ameluz®-PDT for AKs on peripheral body areas has completed the treatment phase, with database lock achieved for the treatment phase data. A one-year follow-up phase is ongoing, though the company notes that this follow-up is not required for FDA approval of the indication.
• Phase 1 pharmacokinetics study: An open-label Phase 1 maximal-use study assessed the pharmacokinetic profile of 5‑aminolevulinic acid (ALA) and its metabolite protoporphyrin IX (PpIX) following application of Ameluz® over a defined treatment area on peripheral body regions, using the BF‑RhodoLED® XL lamp.
• Superficial basal cell carcinoma sNDA: Biofrontera has submitted an sNDA to the FDA for Ameluz®-PDT in sBCC, supported by a double-blind, randomized, placebo-controlled, multi-center Phase 3 trial in patients with clinically and histologically confirmed superficial BCCs. The company reports that primary and key secondary endpoints were met with high statistical significance, with favorable one-year recurrence and aesthetic outcomes.
• Acne vulgaris Phase 2 study: A Phase 2 clinical study evaluating Ameluz®-PDT for moderate to severe acne vulgaris has completed the active treatment phase, and the database for the treatment phase has been locked. The company indicates that these data are intended to support future Phase 3 development and potential regulatory interactions.

Through these programs, Biofrontera is working to expand the labeled indications for Ameluz®-PDT beyond its current use in treating actinic keratoses on the face and scalp, with the stated goal of broadening its role in dermatologic oncology and inflammatory skin disease.

Capital markets and listing status

Biofrontera’s common stock trades on The Nasdaq Stock Market LLC under the symbol BFRI. The company has also registered warrants to purchase common stock (trading under the symbol BFRIW) and has preferred stock purchase rights listed on Nasdaq.

In 2025, Biofrontera received notices from Nasdaq regarding non-compliance with certain continued listing requirements, including the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) and the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Subsequent filings report that Nasdaq notified the company it had regained compliance with both rules, based on stockholders’ equity levels following its strategic transaction and private placement of preferred stock, and based on its common stock closing bid price trading at or above the required threshold for the requisite number of consecutive business days.

The company has also completed private placements of convertible preferred stock (Series C and Series D) with accredited investors, with the stated purpose of funding the acquisition and transfer costs associated with the strategic transaction for the U.S. rights to Ameluz® and RhodoLED®, as well as for general corporate purposes.

Business model characteristics

From its public statements, Biofrontera’s business model can be characterized by the following elements:

• Commercialization of dermatologic PDT products in the United States, primarily Ameluz® and the RhodoLED® lamp series, for the treatment of actinic keratoses.
• Clinical and regulatory expansion of its PDT platform into additional indications such as AK on peripheral body areas, superficial basal cell carcinoma, and acne vulgaris.
• Ownership and control of key U.S. assets and IP related to Ameluz® and RhodoLED®, enabling the company to manage manufacturing, regulatory strategy, and commercialization directly.
• Portfolio rationalization through divestiture of non-core assets, such as the Xepi® antibiotic cream license, to focus resources on its PDT franchise.

According to its financial updates, Biofrontera’s revenues are derived from sales of its dermatological products, particularly Ameluz®-PDT treatments, and it emphasizes the importance of expanding the installed base of RhodoLED® lamps to support recurring Ameluz® gel usage.

Risk and regulatory considerations

As a biopharmaceutical company, Biofrontera’s operations are subject to U.S. Food and Drug Administration (FDA) regulation and other applicable laws and regulations. The company’s forward-looking statements highlight risks related to reliance on sales of its products as its sole source of revenue, competition from other pharmaceutical and medical device companies and existing treatments, the availability of insurance coverage and reimbursement, the ability of manufacturing partners to supply products in sufficient quantities and quality, intellectual property protection, access to additional financing, and continued compliance with Nasdaq listing standards.

FAQs about Biofrontera Inc. (BFRI)

• What does Biofrontera Inc. do?
  Biofrontera Inc. is a U.S.-based biopharmaceutical company that commercializes pharmaceutical products for dermatological conditions using photodynamic therapy (PDT). Its products are used for the treatment of actinic keratoses and are in development for additional skin disease indications.
• What are Biofrontera’s main products?
  The company’s main products are Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, and the RhodoLED® and BF‑RhodoLED® XL red light lamps. Together, these are used in photodynamic therapy for the treatment of actinic keratoses and are being studied for broader dermatologic uses.
• Which skin conditions does Biofrontera target?
  Biofrontera targets dermatologic conditions treated with PDT, including actinic keratoses, which are pre-cancerous skin lesions. It is also developing Ameluz®-PDT for additional indications such as actinic keratoses on peripheral body areas, superficial basal cell carcinoma, and moderate to severe acne vulgaris.
• How is Biofrontera expanding the use of Ameluz®-PDT?
  The company is conducting and has completed clinical studies, including Phase 3 trials in actinic keratoses on the extremities, neck and trunk, a Phase 1 pharmacokinetics study under maximal-use conditions, a Phase 3 trial in superficial basal cell carcinoma, and a Phase 2 trial in acne vulgaris. It has submitted an sNDA for superficial basal cell carcinoma and plans additional regulatory submissions to expand the Ameluz® label.
• What was the strategic transaction with Biofrontera AG?
  Biofrontera Inc. entered into agreements with its former parent company, Biofrontera AG, to acquire all U.S. rights and assets related to Ameluz® and RhodoLED®. This includes the NDA, IND, manufacturing rights and contracts, intellectual property, and related personnel, along with a new earnout structure based on U.S. net sales of Ameluz®.
• Why did Biofrontera divest the Xepi® antibiotic cream license?
  The company sold its U.S. license for Xepi® (ozenoxacin) Cream, 1% to Pelthos Therapeutics Inc. Biofrontera has stated that the proceeds are intended to strengthen its balance sheet and support the growth of its photodynamic therapy platform and the expansion of Ameluz® into additional indications.
• On which exchange does Biofrontera trade and under what symbols?
  Biofrontera’s common stock trades on The Nasdaq Stock Market LLC under the symbol BFRI. Warrants to purchase common stock trade under the symbol BFRIW, and preferred stock purchase rights are also listed on Nasdaq.
• Has Biofrontera faced any Nasdaq listing compliance issues?
  In 2025, Biofrontera received Nasdaq notices regarding non-compliance with the minimum stockholders’ equity requirement and the minimum bid price requirement. Subsequent Nasdaq notices reported that the company had regained compliance with both rules after completing its strategic transaction, private placements, and meeting the bid price threshold for the required period.
• How does Biofrontera describe the importance of actinic keratosis?
  The company describes actinic keratosis as the most common pre-cancerous skin lesion caused by chronic sun exposure, which may progress to squamous cell carcinoma if left untreated. AKs typically appear on sun-exposed areas, and millions of people in the U.S. are affected, with many treatments performed annually.
• What is Biofrontera’s geographic focus?
  Biofrontera identifies itself as a U.S.-based biopharmaceutical company and emphasizes its commercialization and regulatory activities related to Ameluz® and RhodoLED® in the United States.